New method of use patent covers key aspects of the technology that enable patients to receive treatment from the privacy of their own homes
HOUSTON, TX, April 04, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the "Company" or "Nexalin") (Nasdaq: NXL; NXLIW) today announced that the United States Patent and Trademark Office (USPTO) has awarded U.S. Patent No. 17/337,653 relating to the Company's non-invasive, frequency-based deep brain stimulation device. The newly issued patent, entitled, "Transcranial Alternating Current Dynamic Frequency Stimulation Method for Anxiety, Depression and Insomnia (ADI)," covers the method of use utilized in the Company's Gen-3 HALO Clarity system.
Mark White, CEO of Nexalin Technology, stated, "This method of use patent award marks a major achievement for the Company and follows another recent patent covering our core technology. These patents extend through 2040 and are a critical element of our overall strategy, given the mounting clinical data supporting the benefits of our noninvasive, deep frequency brain stimulation technology in the fields of insomnia, depression, and anxiety. A key differentiator for our new Gen-3 HALO Clarity is that, for the first time, it enables patients to receive this treatment in the privacy of their own homes with remote monitoring by a physician in Nexalin's Virtual Clinic."
"Importantly, we are advancing our strategy for regulatory clearance in the U.S., while focusing on commercial rollout in a variety of overseas markets. Overall we are more confident than ever in the outlook for the business and our potential to transform the standard of care for the treatment of mental health disorders, as well as reducing the growing dependence on drugs that are often ineffective and may have undesirable side effects."
The Gen-3 system reflects state-of-the-art development of Nexalin's Deep Intracranial Frequency Stimulation (DIFS) technology, and a significant advancement to the predecessor Gen-1 system. The Company's technology uses a digital breakthrough in electrical waveforms to provide deep and painless brain neural stimulation. The Gen-3 system is applied through the placement of strategically positioned electrodes on the patient's cranium, and provides deep stimulation to regions of the brain associated with mental health conditions.
新的使用方法專利涵蓋了該技術的關鍵方面，使患者能夠在自己的家中私密地接受治療
德克薩斯州休斯頓，2024年4月4日（GLOBE NEWSWIRE）——Nexalin Technology, Inc.（“公司” 或 “Nexalin”）（納斯達克股票代碼：NXL；NXLIW）今天宣佈，美國專利商標局（USPTO）已授予與該公司非侵入性、基於頻率的深部腦刺激設備相關的第17/337,653號美國專利。新發布的專利名爲 “治療焦慮、抑鬱和失眠的經顱交流電動態頻率刺激方法（ADI）”，涵蓋了該公司第三代HALO Clarity系統中使用的使用方法。
Nexalin Technology首席執行官馬克·懷特表示：“這項使用方法專利獎標誌着公司的一項重大成就，也是繼最近又一項涵蓋我們核心技術的專利之後。這些專利有效期至2040年，是我們總體戰略的關鍵要素，因爲越來越多的臨床數據支持我們的無創深頻腦刺激技術在失眠、抑鬱和焦慮領域的益處。我們的新Gen-3 HALO Clarity的一個關鍵差異化因素是，它首次使患者能夠在自己的家中私密地接受這種治療，並由Nexalin虛擬診所的醫生進行遠程監控。”
“重要的是，我們正在推進我們在美國的監管許可戰略，同時專注於在各種海外市場進行商業推廣。總體而言，我們對業務前景以及我們改變心理健康障礙治療標準以及減少對通常無效且可能產生不良副作用的藥物日益增長的依賴的潛力比以往任何時候都更加有信心。”
第三代系統反映了Nexalin的深層顱內頻率刺激（DIFS）技術的最新發展，以及對前代第一代系統的重大進步。該公司的技術利用電波形的數字突破來提供深度而無痛的大腦神經刺激。Gen-3系統通過在患者顱骨上放置戰略位置的電極來應用，爲與心理健康狀況相關的大腦區域提供深度刺激。
